Scienture Holdings Inc. (Scienture (SCNX)) just got some good news ahead of its big product launch. The company announced Tuesday that its opioid overdose treatment, Rezenopy (naloxone HCl) Nasal Spray 10 mg, has been added to the formulary of a large national health plan. That means both commercial and Medicare supplemental coverage is now in place, just in time for the planned mid-July 2026 launch.

This isn't a small step. The addition pushes potential access to more than 100 million covered lives across the U.S., according to the company. It's a key piece of Scienture's commercialization strategy for Rezenopy, which is the highest FDA-approved naloxone dose per nasal spray available in the country. The single-use spray delivers 10 mg of naloxone hydrochloride and is meant for emergency treatment of known or suspected opioid overdoses.

To put the market in perspective, Scienture cites IQVIA data for the 12 months ending April 2026: annual U.S. naloxone sales hit about $144 million, with unit volume reaching 9.8 million units. That's a sizable and growing market, and Scienture is positioning Rezenopy as a differentiated product with its higher dose.

The commercial rollout is gaining momentum. Scienture is pursuing a multi-channel strategy targeting institutional, government, and commercial customers. To support the nationwide launch, the company recently expanded its commercial team by adding three sales representatives focused on driving adoption across institutional and commercial markets.

This latest coverage expansion follows Group Purchasing Organization agreements secured back in March 2026. Those deals gave Rezenopy commercial access across more than 5,000 healthcare facilities and created the potential to reach over 60% of the U.S. institutional naloxone market. So the formulary addition is another piece falling into place.

Executive Chairman and co-CEO Shankar Hariharan highlighted the opportunity, noting that Rezenopy enters a large and expanding naloxone market with a differentiated profile as the highest FDA-approved naloxone dose per nasal spray available in the country. The company also has some intellectual property protection: in January, the U.S. Patent and Trademark Office issued a patent covering Rezenopy, effective January 6, 2026, with an expiry date of February 5, 2041. That gives Scienture a long runway.

As for the stock, Scienture shares were down 0.28% at $0.35 during premarket trading on Tuesday. But with coverage expanding and launch approaching, the company is building its case.